- Home
- MRM vs ACXP Comparison
MRM vs ACXP Comparison
Compare MRM & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- ACXP
- Stock Information
- Founded
- MRM 2000
- ACXP 2017
- Country
- MRM Japan
- ACXP United States
- Employees
- MRM N/A
- ACXP N/A
- Industry
- MRM Other Consumer Services
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- ACXP Health Care
- Exchange
- MRM Nasdaq
- ACXP Nasdaq
- Market Cap
- MRM 10.4M
- ACXP 9.1M
- IPO Year
- MRM 2020
- ACXP 2021
- Fundamental
- Price
- MRM $2.19
- ACXP $4.44
- Analyst Decision
- MRM
- ACXP Strong Buy
- Analyst Count
- MRM 0
- ACXP 3
- Target Price
- MRM N/A
- ACXP $143.67
- AVG Volume (30 Days)
- MRM 6.6M
- ACXP 56.1K
- Earning Date
- MRM 05-20-2025
- ACXP 08-12-2025
- Dividend Yield
- MRM N/A
- ACXP N/A
- EPS Growth
- MRM 27.65
- ACXP N/A
- EPS
- MRM 0.18
- ACXP N/A
- Revenue
- MRM $52,786,758.00
- ACXP N/A
- Revenue This Year
- MRM N/A
- ACXP N/A
- Revenue Next Year
- MRM N/A
- ACXP N/A
- P/E Ratio
- MRM $14.33
- ACXP N/A
- Revenue Growth
- MRM 21.55
- ACXP N/A
- 52 Week Low
- MRM $0.34
- ACXP $3.80
- 52 Week High
- MRM $8.39
- ACXP $47.80
- Technical
- Relative Strength Index (RSI)
- MRM 64.42
- ACXP 26.56
- Support Level
- MRM $1.10
- ACXP $4.17
- Resistance Level
- MRM $3.53
- ACXP $9.96
- Average True Range (ATR)
- MRM 0.33
- ACXP 0.80
- MACD
- MRM 0.13
- ACXP -0.29
- Stochastic Oscillator
- MRM 44.81
- ACXP 11.55
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.